Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 104 Colorectal Neoplasms 63 Stomach Neoplasms 49 Rectal Neoplasms 42 Colonic Neoplasms 24 Neoplasm Metastasis 21 Nasopharyngeal Carcinoma 19 Triple Negative Breast Neoplasms 18 Pancreatic Neoplasms 14 Parkinson Disease 4, Autosomal Dominant Lewy Body 12 Neoplasms 12 Gallbladder Neoplasms 7 Cholangiocarcinoma 7 Adenocarcinoma 6 Esophageal Neoplasms 5 Biliary Tract Neoplasms 5 Adenocarcinoma Of Esophagus 5 Esophageal Squamous Cell Carcinoma 4 Neuroendocrine Tumors 3 Gastrointestinal Neoplasms 3 Digestive System Neoplasms 3 Bile Duct Neoplasms 3 Recurrence 2 Pathologic Complete Response 2 Liver Neoplasms 2 Intestinal Neoplasms 2 Hand-Foot Syndrome 2 HER2-positive Advanced Breast Cancer 2 HER2 Positive Metastatic Breast Cancer 2 Drug-Related Side Effects and Adverse Reactions 2

Interventions

trifluridine tipiracil drug combination 1 regorafenib 1 Oxaliplatin 1 Immune Checkpoint Inhibitors 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Spinocerebellar Degenerations × Capecitabine × Clear all

NCT07551479 2026-04-24

TORCH-STAR

Fudan University

Phase 3 Not yet recruiting

Spinocerebellar Degenerations

Data powered by HemOnc (CC BY 4.0) Colophon ⚡